No Data
JMP Securities Maintains CureVac(CVAC.US) With Buy Rating, Maintains Target Price $18
JMP Securities analyst Roy Buchanan maintains $CureVac(CVAC.US)$ with a buy rating, and maintains the target price at $18.According to TipRanks data, the analyst has a success rate of 33.0% and a tota
Buy Rating on CureVac: Positive Financial Outlook and Promising Vaccine Trials Fuel Optimism
CureVac's Cash And Cash Equivalents Position Of €300.2M As Of March 31, 2024; Reaffirming Cash Runway Into Fourth Quarter Of 2025
CureVac's Cash And Cash Equivalents Position Of €300.2M As Of March 31, 2024; Reaffirming Cash Runway Into Fourth Quarter Of 2025
CureVac Reported Q1 2024 Pre-Tax Loss Of €69.9M Vs. €57.4M YoY
CureVac Reported Q1 2024 Pre-Tax Loss Of €69.9M Vs. €57.4M YoY
CureVac Q1 2024 Sales €12.400M Beat €12.030M Estimate
CureVac Q1 2024 Sales €12.400M Beat €12.030M Estimate
Daily Ticket Tracking | Bulls in ecstasy! Nvidia's stock price topped $1,000 before the market; another big winner in the AI craze! The first solar call single surged 670 times
The spread of bird flu caused panic, and US vaccine stocks such as Pfizer rallied higher. The share option caused volatility to rise to 45% during the year, and trading volume surged nearly fivefold from month to month.